Rucaparib (Rubraca) significantly improved radiographic progression-free survival (rPFS) vs physician’s choice of docetaxel or androgen receptor pathway inhibition (ARPI) in patients with BRCA-mutated metastatic castration-resistant prostate…
Updated TRITON3 Data Support Rucaparib in BRCA-Mutated mCRPC Regardless of Age
